Physician profile
Jerrold S Canakis
NPI 1700874179
$15,005.06
in general payments reported to CMS, 2019-2025
38 companies · $2,868 in 2025
The $2,868 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $1,013 · 2021: $1,353 · 2022: $2,113 · 2023: $2,684 · 2024: $3,397 · 2025: $2,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,927 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,927.39 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,168.35 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,379.77 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,133.74 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,003.91 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $970.57 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $554.46 | 2022-2025 | Sucraid, Sucraid |
| Celgene Corporation | $526.69 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $476.70 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $448.55 | 2023-2025 | Voquezna |
| Pfizer INC. | $428.44 | 2019-2025 | |
| Boston Scientific Corporation | $407.02 | 2019-2025 | Wallflex Duodenal, Axios |
| Braintree Laboratories, INC. | $349.24 | 2019-2023 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $337.97 | 2019-2024 | Stelara |
| Ardelyx, INC. | $313.84 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $290.13 | 2019-2024 | Rebyota, Cimzia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $286.62 | 2023-2025 | |
| Gilead Sciences, INC. | $273.68 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $272.93 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $266.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $210.89 | 2023 | Interstim |
| Novo Nordisk INC | $159.26 | 2025 | Wegovy |
| Allergan, INC. | $131.58 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $97.22 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.10 | 2024 | Cyltezo |
| Daiichi Sankyo INC. | $70.90 | 2020-2022 | |
| Amgen INC. | $65.52 | 2023 | Avsola, Amjevita |
| Olympus America INC. | $43.41 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $43.13 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $38.98 | 2021 | |
| Exact Sciences Corporation | $24.81 | 2023 | Cologuard Collection Kit |
| Vivus LLC | $23.50 | 2024 | Pancreaze |
| Celltrion USA INC. | $22.08 | 2025 | Vegzelma |
| Lilly USA, LLC | $20.00 | 2024 | Omvoh |
| Alnylam Pharmaceuticals INC. | $19.84 | 2025 | Givlaari |
| Sandoz INC. | $19.38 | 2024 | Hyrimoz |
| Conmed Corporation | $17.08 | 2023 | Conmed Polypectomy, Conmed Hemostasis |
| Merck Sharp & Dohme LLC | $13.95 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $10.41 | 2024 | Sureclip, Inflation Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrold Canakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.